Shields Matthew 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
TEVA EVP Matthew Shields Sells 17,295 Shares
What Happened
Matthew Shields, EVP, Global Operations of Teva Pharmaceutical Industries (TEVA), had 17,295 restricted share units vest and convert into ordinary shares on March 5, 2026, and sold 17,295 shares in an open‑market transaction for total proceeds of $547,705 (weighted average price $31.67). A related derivative disposition of shares for tax withholding was reported at $0 per share. The sale was executed under a Rule 10b5‑1 trading plan.
Key Details
- Transaction date: March 5, 2026. Form 4 filed March 9, 2026 (within the usual two-business-day deadline).
- Open-market sale: 17,295 shares at a weighted average price of $31.67; proceeds $547,705. Reported sale prices ranged $31.26–$32.34.
- Derivative/conversion: 17,295 RSUs converted to shares (reported as exercise/conversion). A separate derivative disposition of 17,295 shares at $0 was reported for tax withholding.
- Plan/footnotes: Transactions effected pursuant to a 10b5‑1 plan adopted Nov 10, 2025. RSUs were originally granted Mar 5, 2025 with vesting schedule (17,295 vesting each Mar 5 in 2026–2028; 17,297 in 2029).
- Shares owned after the transactions: not disclosed in the provided filing.
- ADS note: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).
Context
This was a vesting/conversion of restricted share units followed by an immediate sale (common for settlement and tax obligations). The filing is factual: it does not indicate intent or sentiment. Purchases tend to be more informative about insider conviction; this is a routine sale tied to RSU vesting and executed under a preexisting 10b5‑1 plan.
Insider Transaction Report
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-05+17,295→ 27,284 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-05$31.67/sh−17,295$547,705→ 9,989 total - Exercise/Conversion
Restricted Share Units
[F2][F6][F1]2026-03-05−17,295→ 51,887 total→ Ordinary Shares (17,295 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
- [F4]Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029.